Currently, there are 66.38M common shares owned by the public and among those 64.51M shares have been available to trade.
The company’s stock has a 5-day price change of -0.49% and -4.59% over the past three months. CLDX shares are trading -19.47% year to date (YTD), with the 12-month market performance down to -45.98% lower. It has a 12-month low price of $14.40 and touched a high of $47.00 over the same period. CLDX has an average intraday trading volume of 797.60K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.42%, 6.39%, and -22.43% respectively.
Institutional ownership of Celldex Therapeutics Inc (NASDAQ: CLDX) shares accounts for 109.42% of the company’s 66.38M shares outstanding.
It has a market capitalization of $1.35B and a beta (3y monthly) value of 1.35. The earnings-per-share (ttm) stands at -$2.70. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.14% over the week and 4.64% over the month.
Earnings per share for the fiscal year are expected to decrease by -40.77%, and -15.49% over the next financial year. EPS should shrink at an annualized rate of -16.88% over the next five years, compared to 6.91% over the past 5-year period.
Looking at the support for the CLDX, a number of firms have released research notes about the stock. Canaccord Genuity stated their Buy rating for the stock in a research note on April 28, 2025, with the firm’s price target at $64. Morgan Stanley coverage for the Celldex Therapeutics Inc (CLDX) stock in a research note released on March 20, 2025 offered a Overweight rating with a price target of $46. UBS was of a view on February 13, 2025 that the stock is Buy, while Citigroup gave the stock Buy rating on October 07, 2024, issuing a price target of $70. Goldman on their part issued Neutral rating on September 30, 2024.
